SINK SIDE
NOTESSKIN-CARE DECISIONPRACTICAL CALL

U.S. ROUTINE CONTEXT · PRACTICAL CALL

Smooth rough or dull-looking skin without over-exfoliating

Choose an exfoliation approach that improves surface appearance without chasing redness as proof of activity.

NOTE 01

OUR SINK-SIDE CALL

The route we would take.

Use one exfoliant and start infrequently

NOTE 02

Where the call changes.

CHOOSE DIFFERENTLY WHEN

  • Tingling or redness is not evidence that an exfoliant is working better.
  • Persistent scaling or inflammation is outside a simple cosmetic comparison.

WHAT WE ARE NOT CLAIMING

  • Exact concentrations, material origin and quality, reformulation history, and online ingredient-list synchronization are often missing.

NOTE 03

HOW TO READ THIS NOTE

Evidence without theater.

This page makes an editorial call from documented context. It does not claim a product was owned, used, ranked, or independently tested. Manufacturer statements never become our results.

EVIDENCE TRAIL

What the sources carry — and what the desk decides.

The linked sources support product status, labeling, or professional boundaries. They do not prove the editorial winner and they do not stand in for an owned test.

EDITORIAL JUDGMENT

Use one exfoliant and start infrequently

A reasoned course of action; not a product result measured by the source.
BOUNDARY OF THE CALL

Tingling or redness is not evidence that an exfoliant is working better.

Exact concentrations, material origin and quality, reformulation history, and online ingredient-list synchronization are often missing.

Primary and professional sources in the record

  1. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)U.S. Food and Drug Administration
  2. Cosmetics Labeling ClaimsU.S. Food and Drug Administration
  3. Summary of Cosmetics Labeling RequirementsU.S. Food and Drug Administration
  4. 21 CFR Part 701 — Cosmetic LabelingOffice of the Federal Register / eCFR
  5. 21 CFR Part 740 — Cosmetic Product Warning StatementsOffice of the Federal Register / eCFR
  6. FDA Adverse Event Monitoring System (AEMS)U.S. Food and Drug Administration
Data and test conditions still required
Product function and category

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Ingredient list for the current version

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Body area and directions

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Amount, contact time, and frequency

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Performance under realistic use

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Tolerance protocol and stop criteria

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Track exfoliation dose, frequency, and response

Define and retain the conditions, date, material, and outcome before presenting any owned observation.

Assess general tolerance with stop rules

Define and retain the conditions, date, material, and outcome before presenting any owned observation.

Separate cosmetic skin care from medical review

Define and retain the conditions, date, material, and outcome before presenting any owned observation.